Emerging evidence suggests that BCL6B is closely associated with the initiation, progression, and clinical outcomes of multiple malignancies, including hepatocellular carcinoma (HCC), gastric cancer (GC), breast cancer (BC), colorectal cancer (CRC), lung cancer (LC), thyroid cancer (TC), cervical cancer (CC), renal cell carcinoma (RCC), differentiated thyroid carcinoma (DTC), and lymphomas. This evidence concerns the gene BCL6B and renal cell carcinoma.